Â鶹ŮÓÅ

The Obama administration's "cancer moonshot" took a major step forward Wednesday when a committee of top cancer researchers and patient advocates recommended an ambitious set of scientific goals designed to sharply accelerate progress against the disease. The 10 ideas, which were developed by a blue-ribbon panel, deal with an array of topics, including research, clinical trials, data mining, prevention and patient engagement. The recommendations were sent to a task force headed by Vice President Biden, who is leading the administration's moonshot campaign. (McGinley, 9/7)

The U.S. Food and Drug Administration will review Merck & Co.’s immunotherapy cancer drug Keytruda as a first-line treatment for patients with the most common form of lung cancer, the company said Wednesday. The FDA granted Keytruda, or pembrolizumab, breakthrough therapy designation and priority-review status with a target action date of Dec. 24. (Steele, 9/7)